Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Transcription Factors in Cancer 2.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Transcription Factors in Cancer 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 4700

Special Issue Editors

Dr. Tomasz Wilanowski

E-Mail Website
Guest Editor
Faculty of Biology, Institute of Genetics and Biotechnology, University of Warsaw, Pawinskiego 5a, 02-106 Warsaw, Poland
Interests: transcription factors; Grainyhead-like; regulation of gene expression; oncogenes; tumor suppressors; drug targets; phosphorylation; post-translational modifications; skin cancer; renal cancer; somatic mutations in cancer; polymorphisms including single nucleotide polymorphisms; mammalian embryonic development
Special Issues, Collections and Topics in MDPI journals
Dr. Seb Dworkin

E-Mail Website
Guest Editor
Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University, Bundoora, VIC 3086, Australia
Interests: transcription factors; Grainyhead-like; skin cancer; brain cancer; mammalian embryonic development; lung morphogenesis; zebrafish embryonic development; craniofacial development; brain development; neurogenesis; epidermal disorders; wound healing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Transcription factors constitute the largest functional class of proteins in all living organisms. They regulate the expression of all genes and by doing so they control virtually every process in every living cell. Transcription factors are also very important in cancer, and many are frequently mutated in cancer. Some of them perform oncogenic functions, while others serve as tumor suppressors. Some polymorphisms in genes coding for transcription factors can be used to identify people with an increased risk of cancer. Transcription factors can also serve as biomarkers to monitor the progression of this disease. Their activity can be regulated post-translationally, by post-translational modifications or ligand binding (in nuclear receptors). Nowadays, it is possible to modulate the activity of transcription factors using small molecule inhibitors, many of which have already found clinical applications in the treatment of cancer. This Special Issue will focus on recent developments regarding the role of transcription factors in various types of cancer, as well as on applications of this knowledge for the prevention and treatment of cancer. We invite scientists in the broad field of transcription factors in all types of cancer to contribute to this Special Issue.

Dr. Tomasz Wilanowski
Dr. Seb Dworkin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transcription factor
  • oncogene
  • tumor suppressor
  • nuclear receptor
  • posttranslational regulation
  • biomarker
  • drug target
  • small molecule inhibitor

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3196 KiB  
Article
New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
by Fanjia Zhao, Fang Yan and Haihong Liu
Int. J. Mol. Sci. 2023, 24(4), 4058; https://doi.org/10.3390/ijms24044058 - 17 Feb 2023
Viewed by 1869
Abstract
Dendritic cells(DCs) play a protective role in the antitumor immunity of most cancers, which can be divided into conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). Most current studies are only based on either cDCs or pDCs for the study of the [...] Read more.
Dendritic cells(DCs) play a protective role in the antitumor immunity of most cancers, which can be divided into conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). Most current studies are only based on either cDCs or pDCs for the study of the relationship between DCs and breast cancer prognosis, without combining the two together. We aimed to select new biomarkers from pDCs and cDCs. In this paper, the xCell algorithm was first used to calculate the cellular abundance of 64 types of immune cells and stromal cells in tumor samples from the TCGA database, and the high-abundance pDC group and cDC group were divided according to the results of a survival analysis. Then, we looked for the co-expressed gene module of highly infiltrating pDC and cDC patients with a weighted correlation network analysis (WGCNA) and screened out the hub genes, including RBBP5, HNRNPU, PEX19, TPR, and BCL9. Finally, we analyzed the biological functions of the hub genes, and the results showed that RBBP5, TPR, and BCL9 were significantly related to the immune cells and prognosis of patients, and RBBP5 and BCL9 were involved in responding to TCF-related instructions of the Wnt pathway. In addition, we also evaluated the response of pDCs and cDCs with different abundances to chemotherapy, and the results showed that the higher the abundance of pDCs and cDCs, the higher their sensitivity to drugs. This paper revealed new biomarkers related to DCs—among them, BCL9, TPR, and RBBP5 were proven to be closely related to dendritic cells in cancer. For the first time, this paper puts forward that HNRNPU and PEX19 are related to the prognosis of dendritic cells in cancer, which also provides new possibilities for finding new targets for breast cancer immunotherapy. Full article
(This article belongs to the Special Issue Transcription Factors in Cancer 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 946 KiB  
Review
The Role of REV-ERB Receptors in Cancer Pathogenesis
by Georgia Gomatou, Anastasia Karachaliou, Orsalia-Zoi Veloudiou, Alexandra Karvela, Nikolaos Syrigos and Elias Kotteas
Int. J. Mol. Sci. 2023, 24(10), 8980; https://doi.org/10.3390/ijms24108980 - 19 May 2023
Cited by 2 | Viewed by 2128
Abstract
REV-ERB receptors are members of the nuclear receptor superfamily of proteins, which act as both intracellular receptors and transcription factors, therefore modulating the expression of target genes. REV-ERBs act as transcription repressors because of their unique structure. Their predominant role involves the control [...] Read more.
REV-ERB receptors are members of the nuclear receptor superfamily of proteins, which act as both intracellular receptors and transcription factors, therefore modulating the expression of target genes. REV-ERBs act as transcription repressors because of their unique structure. Their predominant role involves the control of peripheral circadian rhythmicity by participating in a transcription–translation feedback loop with other major clock genes. Regarding their role in cancer pathogenesis, recent studies in various cancerous tissues have revealed that their expression was downregulated in the majority of the cases. Dysregulation of their expression was also implicated in cancer-associated cachexia. The pharmacological restoration of their effects is feasible with synthetic agonists, which have been explored in preclinical studies but with scarce data. There is a need for further investigation, primarily with mechanistic studies, on the effect of the REV-ERB-induced circadian rhythm deregulation in carcinogenesis and cancer-related systemic effects, such as cachexia, in order to address the potential of relevant therapeutic implications. Full article
(This article belongs to the Special Issue Transcription Factors in Cancer 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop